After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.
As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.Zhongwei company is a company engaged in the research, development, production and sales of high-end semiconductor equipment and pan-semiconductor equipment. Great Wall Securities said that the company's etching, thin film deposition and MOCVD equipment have reached the international advanced level.In the secondary market, the concept stocks of M&A and restructuring rose strongly, and the restructuring index rose nearly 63% since September 24th.
As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.
Strategy guide 12-13
Strategy guide
Strategy guide
12-13
Strategy guide
12-13